BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX EBITDA Margin
EBITDA as a percentage of revenue.
BioNTech SENASDAQ: BNTX
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to -553.7%
EBITDA Margin was -553.7% in Q2 FY2026, down 420.1 pp from a year earlier. On a trailing-twelve-month basis it was -35.6%, down 34.2 pp year over year. Over 3 fiscal years it narrowed by 98.4 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 11 analysts of -55.5% for the fiscal year ending Dec 2026, down from -22.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -553.7%-178.8 pp QoQ
- Last fiscal yearDec 2025
- -22.8%-9.4 pp YoY
- LTMJun 2026
- -35.6%-34.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -22.8%
- Year-over-year change
- -9.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -22.8% | -9.4pp |
| FY2024 | 2024-12-31 | -13.3% | -49.4pp |
| FY2023 | 2023-12-31 | 36.1% | -39.6pp |
| FY2022 | 2022-12-31 | 75.7% | -3.4pp |
| FY2021 | 2021-12-31 | 79.1% | — |
EBITDA Margin vs competitors
How BNTX compares with its peers on the latest reported figures
- BNTX's LTM Jun 2026 EBITDA Margin of -35.6% is the 7th highest of the 11 companies compared; the peer median is -15.3%.
- Its year-over-year change of -34.2 pp is the 7th highest of 10, against a peer median of -0.4 pp.
- Over three fiscal years its change of -98.4 pp compares with a peer median of +26.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 48.0% | +82.8 pp | +491.0 pp | |
| LTM Jun 2026 | 35.5% | +6.0 pp | +16.6 pp | |
| LTM Jun 2026 | 29.5% | — | -14.7 pp | |
| LTM Sep 2026 | 21.3% | -0.4 pp | +7673.7 pp | |
| LTM Mar 2026 | 1.6% | +1.6 pp | +26.7 pp | |
| LTM Mar 2026 | -32.2% | -1.2 pp | +32.0 pp | |
| LTM Jun 2026 | -35.6% | -34.2 pp | -98.4 pp | |
| LTM Sep 2026 | -48.8% | +93.1 pp | — | |
| LTM Jun 2026 | -117.7% | -51.9 pp | -9.6 pp | |
| LTM Mar 2026 | -542.7% | -539.6 pp | -412.4 pp | |
| LTM Sep 2026 | -550.8% | -269.0 pp | +146419.7 pp | |
| Peer median (excluding BNTX) | -15.3% | -0.4 pp | +26.7 pp | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B |
| Cost of Revenue | 2.91B | 3B | 599.8M | 541.3M | 616.47M |
| Gross Profit | 16.07B | 14.32B | 3.22B | 2.21B | 2.14B |
| Gross Margin | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| Research & Development | 949.2M | 1.54B | 1.78B | 2.25B | 2.02B |
| Selling, General & Admin | 327.2M | 541.2M | 557.7M | 599M | 698.2M |
| Operating Expenses | 781.4M | 1.67B | 2.53B | 3.52B | 2.76B |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| EBITDA | 15B | 13.1B | 1.38B | (367.1M) | (628M) |
| EBITDA Margin | 79.1% | 75.7% | 36.1% | -13.3% | -22.8% |
| Operating Income | 15.28B | 12.64B | 690.4M | (1.31B) | (623.87M) |
| Operating Margin | 80.5% | 73.0% | 18.1% | -47.8% | -22.6% |
| Interest Income | 1.56M | 47.37M | 351.31M | 0 | 252.24M |
| Interest Expense | 5.63M | 15.82M | 7.76M | 13.16M | 13.64M |
| Other Income / Expenses | (237.4M) | 311.4M | 495.7M | 636.6M | (385.46M) |
| Income Before Tax | 15.05B | 12.95B | 1.19B | (677.7M) | (1.01B) |
| Pre-Tax Margin | 79.3% | 74.8% | 31.1% | -24.6% | -36.6% |
| Income Tax Expense | 4.75B | 3.52B | 255.8M | (12.4M) | 81.93M |
| Net Income | 10.29B | 9.43B | 930.3M | (665.3M) | (1.09B) |
| Net Margin | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| EPS (Basic) | 43.87 | 38.08 | 3.87 | (2.77) | (4.51) |
| EPS (Diluted) | 41.21 | 37.09 | 3.83 | (2.77) | (4.51) |
| Weighted Avg Shares | 244M | 243.3M | 240.6M | 240.4M | 241.7M |
| Weighted Avg Shares (Diluted) | 259.7M | 249.8M | 242.7M | 240.4M | 241.7M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.